drugset / Trial / NCT03965208

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate heparin as compared to bivalirudin for systemic anticoagulation in adult patients that require extracorporeal membrane oxygenation (ECMO). Half of the participants will receive heparin and half will receive bivalirudin.

Timeline

Start
2019-05-23
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide
Comparator Heparin Other / unclassified

Indications

No indication recorded.